Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature

Malignant pleural effusion (MPE) is a major problem associated with advanced non-small cell lung cancer for which an optimum treatment strategy has yet to be determined. Notably, vascular endothelial growth factor (VEGF) signaling has been found to influence MPE, and bevacizumab, a VEGF ligand inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Ryobu, Fujimoto, Daichi, Ito, Munehiro, Tomii, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564666/
https://www.ncbi.nlm.nih.gov/pubmed/28591698
http://dx.doi.org/10.18632/oncotarget.17952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564666/
https://www.ncbi.nlm.nih.gov/pubmed/28591698
http://dx.doi.org/10.18632/oncotarget.17952

Ejemplares similares